Rocket Pharma (RCKT) opening seller 2000 January $20 puts $2.40 with stock at $20.70, very bullish signal in smaller Bio that dipped to 8-MA after recent surge after FDA alignment on Phase 2 RP-A401 trial design. RCKT has a $1.88B market cap with $307M cash, well-funded through 2025. Rocket is a leader in gene therapy with a robust cardiovascular pipeline and a hematology pipeline